Bioventus - Earnings Call - Q2 2025

Executive Summary

• Q2 2025 delivered resilient execution: revenue $147.7M (-2.4% reported; +6.2% organic), GAAP diluted EPS $0.11 (vs. prior-year -$0.40), and Non-GAAP EPS $0.21 (+31% YoY); adjusted EBITDA was $33.8M with ~23% margin, supported by gross margin mix and disciplined OpEx.
• Against S&P Global consensus, Bioventus posted a modest beat: revenue $147.7M vs. $145.9M*, EPS $0.21 vs. $0.197*, and EBITDA (company non-GAAP) $33.8M vs. $29.9M*; management reaffirmed full-year guidance (net sales $560–$570M, adj. EBITDA $112–$116M, Non-GAAP EPS $0.64–$0.68). Values retrieved from S&P Global.
• Surgical Solutions grew 11.4% YoY, Restorative Therapies grew 11.2% organically (despite divestiture headwind), while Pain Treatments rose 1.5% led by DUROLANE volume; international revenue increased 12.4% (+24.0% organic).
• Strategic catalysts: FDA 510(k) clearances for TalisMann and StimTrial (PNS) with limited launch in Q3 and broader rollout in early 2026, plus a new $400M credit agreement reducing interest margins by 75 bps and extending maturities to 2030.
• Near-term stock reaction drivers: confirmation of non-opioid PNS launch timing and adoption, sustained Ultrasonics capital placements, and reiterated annual guidance despite FX/tariff headwinds (~$5M combined headwinds absorbed year-to-date).

What Went Well and What Went Wrong

What Went Well

• Double-digit growth in Ultrasonics and accelerating Bone Graft Substitutes (BGS) in Surgical Solutions; “we delivered strong double digit growth in ultrasonics…enhanced precision…reduced patient blood loss, and increased OR efficiency”.
• EXOGEN drove double-digit organic growth in Restorative Therapies; management highlighted “improvement in commercial effectiveness and sales force execution” and momentum to return the category above $100M over time.
• Cash generation accelerated: cash from operations $25.9M (+$10.8M YoY), with management targeting net leverage below 2.5x by 2025 and interest savings >$2M annually from the new credit agreement.

What Went Wrong

• FX and tariffs: year-to-date FX headwind >$2M and updated tariff impact ~$3M for 2025; adjusted EBITDA dipped vs. prior year due to divestiture and FX.
• Pain Treatments price pressure and tough comps temporarily slowed growth; management cited lower ASPs and a challenging comparison to prior year despite DUROLANE volume strength.
• Reported revenue decline (-2.4%) reflects the Advanced Rehabilitation divestiture; Restorative Therapies reported -31.6% YoY with only $0.2M of divested revenue remaining in the quarter.

Transcript

Speaker 6

Thank you for standing by. My name is Carly, and I will be your conference operator today. At this time, I would like to welcome everyone to the Bioventus Inc. second quarter 2025 earnings conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, press star one again. Thank you. I would now like to turn the call over to Dave Crawford, Vice President, Investor Relations. Please go ahead.

Speaker 0

Thanks, Carly. Good morning, everyone, and thanks for joining us. It's my pleasure to welcome you to the Bioventus 2025 second quarter earnings conference call. With me this morning are Rob Claypoole, President, CEO, and Mark Singleton, Senior Vice President and CFO. Rob will begin his remarks with an update on our business and our 2025 priorities. Mark will review our second quarter results and discuss our outlook, including our 2025 financial guidance. We will finish the call with Q&A. The presentation for today's call is available on the Investors section of our website, bioventus.com.

Before we begin, I would like to remind everyone that our remarks today contain forward-looking statements that are based on the current market expectations of management and involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including the risks and uncertainties described in the company's filings with the Securities and Exchange Commission, including item 1A risk factors of the company's Form 10-K for the year ended December 31, 2024, as such factors may be updated from time to time in the company's other filings made with the Securities and Exchange Commission. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date made.

Although the company may voluntarily do so from time to time, it undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws. This call will also include reference to certain financial measures that are not calculated in accordance with U.S. generally accepted accounting principles or GAAP. We generally refer to these as non-GAAP or adjusted financial measures. Important disclosures about and definitions and reconciliations of those non-GAAP financial measures to the most comparable measures calculated and presented in accordance with GAAP are available in the earnings press release on the Investors section of our website at bioventus.com. Now I will turn the call over to Rob.

Speaker 2

Thank you, Dave. Good morning, everyone, and thanks for joining our call today. I'm pleased to report that Bioventus delivered another quarter of solid financial results, driven by our team's disciplined execution. As we move into the second half of the year, we are well positioned to accelerate revenue growth, profitability, and cash flow as we help patients recover so they can live life to the fullest. Second quarter revenue of $148 million was in line with our expectations and reflected the strength of our portfolio's diversity as we drove above-market organic growth of 6%, even with challenging prior year comparisons in pain treatments. Adjusted earnings of $0.21 per share increased 31% compared to the prior year, while our adjusted EBITDA margin of 23% for the quarter exemplifies the stability of our pure leading gross margin and disciplined investment and key growth strategies.

As a result of a solid first half and strong outlook for the remainder of the year, we are reiterating our full year revenue, adjusted EBITDA, and adjusted earnings per share guidance. Now let's take a closer look at our second quarter highlights and provide an update on our business across the three priorities I introduced at the start of the year: driving above-market revenue growth, continuing to expand our profitability, and accelerating free cash flow generation. With respect to our first priority, driving above-market revenue growth, let me share a few highlights, starting with our Surgical Solutions business, where we delivered strong double-digit growth in ultrasonics. We are well positioned for sustained above-market revenue growth as we continue to broaden awareness in the market of our ultrasonics value proposition of enhanced precision and control for surgeons, reduced patient blood loss, and increased operating room efficiency.

Switching to our Restorative Therapies business, Exogen accelerated and achieved double-digit growth for the quarter. This performance validates our approach to drive success across all of our product categories at Bioventus: higher focus, the right strategy, targeted investments, and disciplined commercial execution, which we believe will enable us to deliver strong above-market growth. In our Pain Treatments business, as expected, growth temporarily slowed as a result of difficult comparisons to the prior year period. In the second half of this year, we expect pain treatments growth to accelerate as comparisons normalize, and we drive traction with our focused strategy on large accounts, including IDNs. Powered by Durolane, we have a solid platform for sustained above-market growth in HA with our clinical differentiation, dedicated commercial team, strength of our private payer coverage, and significant opportunities for geographic expansion.

Let me take a moment to discuss a key development within our pain treatment business: our recent 510-K clearance of both StimTrial and Talisman for peripheral nerve stimulation, or PNS, for the treatment of chronic peripheral pain. In many cases, patients suffer from debilitating chronic pain that limits their life or work activities on a daily basis. This therapy uses PNS products to deliver electrical pulses to specific peripheral nerves to provide non-opioid relief from chronic pain. The clearance of both StimTrial and Talisman represents a very attractive growth opportunity for Bioventus as we look to expand aggressively in the fast-growing PNS market, which is currently estimated to be growing above 20% annually in the U.S., with revenue expected to exceed $500 million by 2029.

With an expected total addressable market of approximately $2 billion, this represents an exciting expansion opportunity for Bioventus to advance non-opioid minimally invasive solutions for chronic pain management. For those of you who are unfamiliar with our PNS business, our focus until now has centered on our R&D efforts to bring this new technology to market. We've had limited investment and commercial focus for this business, with only a few million dollars in annual revenue from its legacy product offering. With StimTrial, we bring to market our first-ever trial lead designed to allow physicians the ability to evaluate a patient's response to PNS therapy. The lack of a trial lead in our portfolio has significantly limited adoption by physicians historically because physicians often prefer to validate the effectiveness of the treatment before considering a permanent implant and because a trial assessment is required by some payers for reimbursement.

This is complemented by our new Talisman PNS system, which combines our patented electric field conduction technology with an integrated pulse generator to potentially reach deeper, larger nerves. This combination is designed to provide long-term relief from chronic nerve pain for patients, potentially increasing the number of patients who respond to neuromodulation therapy. From a physician's perspective, the increase in power allows for easier lead placement and potentially broadens addressable nerves. Our innovative technology also has a user-friendly interface for both clinicians and patients. This technology reflects our team's world-class R&D capabilities as we bring leapfrog innovation to the market. Over the past few years, we have had a small direct sales force for PNS, which we plan to invest in more over the second half of this year and going forward. We plan a limited commercial release of StimTrial and Talisman in select U.S.

markets starting in this third quarter, with a broader rollout expected in early 2026. For Bioventus, StimTrial and Talisman represent an opportunity to accelerate our growth rate as we see a path to generating an estimated $100 million or more of revenue. We expect the combination of our PNS portfolio with the double-digit growth of our market-leading ultrasonics platform to continue to shift our Bioventus portfolio to higher growth and markets where we can sustainably grow our revenues at above-market rates with differentiated proprietary technology platforms. Before I shift from discussing revenue growth, I'll mention that this was the seventh quarter in a row of at least mid-single-digit growth for Bioventus. While our aspiration and our expectation is much higher, this consistent performance demonstrates the stability and strength of our diverse portfolio.

Turning to our second focus area, expanding profitability, we continue to strongly believe that our pure leading gross margin, combined with acceleration of revenue growth in the second half of the year, will enable us to achieve 100 basis points of adjusted EBITDA margin expansion for the year, despite the negative impact from foreign exchange headwinds that Mark will discuss. With respect to our third focus area, as anticipated, we generated a significant acceleration in cash flow this quarter. We expect this performance to continue into the second half of the year as we benefit from our deleveraging, greater business efficiencies, and reduced extraordinary expenditures to nearly double cash flow from operations compared to the prior year.

In conclusion, we made significant progress this quarter to deliver on our three priorities, and we achieved an important milestone with the 510-K clearance of StimTrial and Talisman, which creates a very attractive long-term growth opportunity for Bioventus. I will also mention that we were recently recognized by U.S. News and World Report as one of the top 10 companies to work for in North Carolina. The combination of very positive employee engagement and improved business performance demonstrates the exciting advancement of our company and that with the right focus, prioritization, and disciplined execution, we will continue marching toward becoming a $1 billion, high growth, high margin, high cash flow company that generates significant value for all of our stakeholders. Now I'll turn the call over to Mark.

Speaker 7

Thanks, Rob, and good morning, everyone. Let me begin by saying that I am pleased with our results and progress through the first half of the year as we work to constantly improve and strengthen our company and our performance. Turning to our headline result for the second quarter, revenue of $148 million was 2% lower than 2023, reflecting the impact of our advanced rehabilitation divestiture at the end of last year. Adjusting for the divestiture, organic growth was 6%, highlighted by strong performance across Surgical Solutions and Restorative Therapies. Adjusted EBITDA of nearly $34 million was $1 million higher than the prior year due to the divestiture and $1 million of foreign currency expense due to the U.S. dollar weakening. Similar to last quarter, the majority of this FX loss resulted from the settlement of payables on our balance sheet.

On a year-to-date basis, we've now absorbed more than $2 million in impacts from unplanned foreign currency exchange rate movements. Now let me provide some additional commentary on our quarterly revenue. Surgical Solutions revenue grew by 11%, driven by strong double-digit growth in ultrasonics. We are also encouraged by the acceleration in growth in bone graft substitutes, which we expect to continue into the second half of the year as new distributors ramp up and existing ones continue to access new customers. In Pain Treatments, revenue increased 1% as we lapped challenging comparisons to the prior year period. Excluding these items, Pain Treatments grew an estimated 4% to 5%. Shifting to Restorative Therapies, the divestiture of advanced rehabilitation business resulted in a 32% decrease in revenue.

Excluding the impact of the divestiture, organic growth was 11% as we accelerated growth in Exogen, which demonstrated improvement in commercial effectiveness and sales force execution, along with the timing of international distributor orders. We are optimistic we will be able to deliver high single to double-digit organic growth for the remainder of the year. Finally, revenue from our international segment increased 12% compared to the prior year, while organic growth climbed 24%. Organic growth was fueled by double-digit growth across Surgical Solutions and Pain Treatments. Moving down the income statement, adjusted gross margin of 76% was 50 basis points higher than last year, driven by improved product mix. Adjusted total operating expenses declined $4 million as increased investment in our growth initiatives was more than offset by direct expense savings related to the advanced rehabilitation divestiture. Now for the additional detail on our bottom line financial metrics.

Adjusted operating income increased $2 million compared to the prior year to $31 million. Adjusted net income of $18 million increased 45% compared to $13 million in the prior year. The growth is a result of our lower interest expense as we continue to pay down debt and benefit from the reduced employee equity-based compensation. Finally, adjusted earnings of $0.21 per share for the quarter, an increase of $0.05 compared to the prior year. Now shifting to the balance sheet and cash flow statement, we ended the quarter with $33 million in cash on hand and $341 million in outstanding debt, which included $5 million drawn on a revolving credit facility. Consistent with our planning assumptions, we realized a significant acceleration in cash flow. Cash flow from operations totaled $26 million, representing an increase of $11 million compared to the prior year.

The stronger cash flow is driven by lower interest expense and a reduction in one-time cash costs. We are confident in our ability to generate significant cash from operations for the remainder of the year, and we continue to expect cash from operations in 2025 to nearly double compared to 2024. Given the projected strong cash flow and increase in adjusted EBITDA, we expect our net leverage will fall to below 2.5 times by the end of 2025. Our strong financial performance and growing cash flow enabled us to recently refinance our credit facility. We entered into a new $300 million five-year term loan agreement and $100 million revolving credit facility with our lenders. We realized several benefits as a result of this refinancing. First, we lowered the interest rate on our debt by 75 basis points, generating annual interest expense savings of over $2 million.

Second, we improved our liquidity and financial flexibility by extending the maturity of our loan to 2030 and increasing the size of our revolver by $60 million. Finally, the annual amortization on the term loan was reduced from 10% to 5% per year for the tenor of the loan. This reduces our annual debt repayment by $15 million, enabling greater opportunity for capital deployment moving forward. To complete the refinancing, we initially drew $30 million on the new revolver and plan to use cash generated in the second half of the year to repay the borrowing on the revolver. By borrowing $30 million on a revolver, we reduced our net debt by an additional $11 million since the end of the second quarter. We believe these are all positive developments for our long-term strategy.

Finally, as Rob mentioned, we are pleased to reaffirm our 2025 financial guidance, which we initially provided on March 11. This includes organic revenue growth of 6% to 8%, adjusted EBITDA of $112 million to $116 million, and EPS of $0.64 to $0.68. Our guidance incorporates the full year impact of $5 million of the current expectation of tariffs in 2025 and the year-to-date impact related to foreign exchange. We now expect the impact of current tariffs to be approximately $3 million in 2025. In addition, we have been successful in offsetting over $2 million related to foreign exchange expense through the first half of the year, and our guidance does not assume additional impact from the U.S. dollar fluctuation in the second half of the year.

In closing, we continue to execute our business plan and believe we are well positioned to create shareholder value through strengthening our growth, profitability, and cash flow over the coming quarters and the long term. Operator, please open the line for questions.

Speaker 6

At this time, I would like to remind everyone, in order to ask a question, press star, then the number one on your telephone keypad. We'll pause for just a moment to compile the Q&A roster. Your first question comes from Chase Knickerbocker with Craig Hallum.

Good morning. Congrats on the solid quarter and thanks for the questions. I wanted to start on pain. Can you remember, I might have missed this, I'm sorry, but can you remind us what growth would have been year over year on an organic basis, if not for that favorable rebate adjustment in Q2 2024? Along those same lines, can you kind of walk through the pluses and minuses in pain in the quarter? It sounds like Durolane volume was a plus. What was the volume growth there for Durolane? You had mentioned kind of price being a bit of a distractor. Was that for Durolane or was that the multi-shot portfolio? If you could just give us your overall thoughts on Jellison and Supartz and the competitive environment for those products as well. Thanks.

Speaker 7

Thanks, Chase. That was a lot of questions, so we'll try to get through. I'll start with the first one and hand it over to Rob. I think when you look at our normalized growth, I talked about that in the script, and essentially it'd be 4% to 5% versus the 1% that we reported.

Speaker 2

Yeah, Chase, for the business overall, feel free to elaborate on your question if this doesn't touch on it, but I think it's important to just keep in mind last year we grew about 4X the market, and as we shared in the beginning of this year, didn't expect that to continue, but really confident that we can grow above the market given the factors we've talked about before with our clinical differentiation, large dedicated commercial team, and our private payer contract strength. As it relates to the competition, this market's been competitive for a long time, and we've been driving above-market growth in that environment and expect to continue to do so.

In terms of across the portfolio, naturally, Durolane continues to be the strongest driver in that portfolio, both with our focus on that and our clinical differentiation, and also as the category continues to shift to single injection. Let us know which aspects of your question we didn't cover there.

Yeah, I threw a lot at you, sorry. Maybe just specifically on Durolane volume growth, if you could elaborate what that was in the quarter. Basically, what I'm trying to get at is in the back half of the year here, you will have to kind of step up organic growth on a year-over-year basis, even from kind of that 4% to 5% range. You know, call it certainly in the high single digits in pain, at least kind of in my model to get to the guidance. Can you just kind of elaborate on kind of the drivers of that acceleration?

Speaker 7

Yeah, Chase, when you think about volume, we just talk about above-market growth from our HA business. You think about the market growth from a single injection for Durolane, which I think is what you're asking about. We think that market grows in the mid-single digits. We were slightly above that for our performance in the second quarter. When you look at the back half of the year, really, from a pain, but overall perspective, when you normalize for the kind of the first half unfavorable compares, we're going to make up half of that, more than half of that growth just with the kind of the one-time compares. We get into the growth drivers in the back half, which is going to be HA and BGS.

I know your question is just about HA specifically, but we have a clear line of sight to some new account wins that have been coming on board over the last few months, and then some new IDN accounts as well that we're looking to accelerate in the back half of the year. We feel confident about it. Just remind you that in that, from an EBITDA perspective, again, not just about pain, we've absorbed $5 million of cost and headwinds between foreign exchange and our tariffs. That's all absorbed in the guidance and feel good about where we are.

Speaker 2

Chase, this is Rob. I'll just elaborate on that a bit to specify a few points to your question. First, when you look at the first half of the year, we grew about 5.5%. To your point, when you look at our full year guidance, it implies an acceleration of about 300 basis points in the second half versus the first half. As Mark touched on, more than half of that, at least half, will come from just getting past the unfavorable comps that we've been talking about. Also, as you touched on, we have BGS, both bone graft substitute, and HA acceleration happening in the second half with new business that we already have visibility to in our pipeline. Just from that combination, let alone the momentum across the rest of our business, that's why we're confident in our revenue guidance for the back half.

That was really helpful, guys. Thanks. Maybe just one more on Surgical Solutions. Can you, you know, what was BGS growth in the quarter? Kind of piecing all this commentary together with ultrasonics, you know, that continuing to do very well and BGS expected to accelerate, should we be expecting accelerating year-over-year growth from the surgical franchise as a whole as we look at the Q3 and Q4 year-over-year growth number compared to Q2?

Speaker 7

Yeah, Chase, I'll just look at your BGS question that you had. I think, you know, in the first quarter, we had really low single digits. When we look at the second quarter, we had pretty much a high single digit growth in the second quarter for BGS. We'd look for that business to continue to accelerate. We've been talking about that since the beginning of the year and still on track for that. From an overall surgical portfolio as well, overall, we're still confident in the growth. I mean, ultrasonics, you know, great portfolio as you've heard us talk about before. With BGS accelerating overall, you know, we feel good about the second half of the year for that business.

Speaker 2

Chase, I'll also touch on this one, just to make sure that I remind you that it's in line with expectations. We're seeing that nice acceleration in bone graft substitutes that we expected, that we've been talking about for a couple of quarters now, and expect that to continue again in the second half as we bring new customers online. Ultrasonics, important to say, it was another very strong quarter of growth. We have this world-class technology, and we believe we can change the standard of care in this space. We're seeing excellent capital placements again, which is a leading indicator of market development, as you know, and we expect our momentum to continue in the second half and then ramp from there in 2026 and beyond. Expect surgical to continue to be a very attractive growth driver for us.

Very helpful. Congrats again on the execution here, guys.

Thanks, Chase.

Speaker 6

Your next question comes from Ross Osborne with Cantor Fitzgerald.

Hey guys, this is Matthew Parkhon for Ross today. Thanks for taking the questions. I guess maybe starting with Exogen, I was hoping to get some more color on what drove strength in the quarter, and I guess your confidence in your ability to sustain growth levels here.

Speaker 2

Thanks, Matthew. In Exogen and our Restorative Therapies business, as mentioned, we generated double-digit growth for Restorative Therapies in the second quarter, so we're very excited about that. That's from a combination of the focus that we're putting on the business, fantastic leadership and team, can't say enough about that team, the right strategy, smart investments, and really stronger commercial execution. That stronger execution is in turn demonstrating a favorable ROI on the investments that we've made in the business. That growth is coming from a combination of previous customers that we'd lost, existing customers driving more volume, and from new customers. Looking forward to keeping this going. I think it's helpful for everybody online to remind them that, as we look forward, this market has an extremely large TAM, or total available market.

It's up to us to go help the unaware and the non-believers so that they can help their patients with what we consider to be remarkable non-invasive technology. We plan on continuing to drive that. We may not be counting on double-digit growth in this business by the quarter, but we do believe we can generate sustained growth in the mid-single digit range or above, while always aiming for higher. Last, Matthew, for your perspective, as you may know, this business used to be over $100 million in size, and we believe we can get it back over $100 million in size with the momentum that we have.

Got it. Super helpful. Maybe one more from me. I guess, how should we think about OPEX spend in the back half of the year, especially as you begin to roll out Talisman and build a sales force there?

Speaker 7

Yeah, thanks for the question. When you look at the back half of the year, we'll see a slight increase in spend on commissions as our BGS revenue ramps, and then we're going to start to do some additional investing in PNS and PRP in the second half of the year. It'll slightly increase, but I think, if you look at our P&L going from 1Q to 2Q, it's really about delivering on the revenue as Rob and myself walked you through that and our confidence in that. When the revenue grows, the EBITDA will come, and we've historically done a good job of being disciplined in managing our spending, and we'll continue to do so.

Got it. Super helpful. Congrats on the quarter, guys.

Thanks, Matthew.

Speaker 6

Your next question comes from Robbie Marcus with J.P. Morgan.

Oh, great. Good morning, and thanks for taking the questions. First for me, I want to ask on R&D, both the absolute dollar spend and percentage of sales, and how you're thinking about that over the future as you start adding more innovative products.

Speaker 2

Hey Robbie, it's Rob. Yeah, we have moderate investment, I'd say, and from an R&D standpoint, that's ramping up with what we've been doing both within our ultrasonics platform and with PNS. For those two businesses, we have what we believe are the best world-class R&D teams internally, and that's why, while we're excited about the existing platforms for both of those, we have strong capabilities to continue to expand those platforms organically. That's where the majority of our R&D dollars are going right now. We expect in both of those businesses for that to increase because, even though we've now launched this very exciting technology with StimTrial and Talisman and PNS, we still have the opportunity to significantly expand that portfolio. We're very committed to that business.

In ultrasonics, we've made a number of changes both in terms of our growth aspirations, what our strategy is to get there, and how our portfolio plays into that. That's included putting stronger resources from an upstream marketing standpoint that are developing our long-term portfolio strategy coming from our overall growth strategy, and that leads to an increase in the R&D spend that we're putting against that business. Moderate so far, but it has been ramping and expected to go up from here as we continue to drive those high-growth businesses.

Speaker 7

I agree with Rob's comments. If you break it down as you look at R&D in total, it might seem on the lower end or to the moderate, but when you break down PNS and ultrasonics portfolio and the amount we're investing in those as a percentage of revenue in the individual portfolios, it's much more a material amount of what you would expect from a med device investment.

Great. Just another question on OPEX. It's a little difficult to tease out what's underlying given the sale of the business. You grew about 6% organic. How should we think about what second quarter and 2025 OPEX growth looks like on an underlying organic basis? Thanks a lot.

I think our revenues are growing faster than our OPEX overall. When you think about the OPEX that we had with our rehabilitation business, it was about $6 million overall from a quarter perspective. That comes down, and then other expenses ramp up. Overall, we're continuing to bring OPEX down from an operational perspective and driving back to our commitment on the 100 basis points margin expansion. It's obviously both the revenue growth with the pure leading gross margin that we're driving and then scaling our OPEX and making sure that the revenue is growing faster than the expense.

Great, thanks a lot.

Speaker 2

Thanks, Robbie.

Speaker 6

Your next question comes from Caitlin Croman with Canaccord Genuity.

Great, thanks for taking the questions. Just on Talisman and StimTrial, any more color on the launch and early commercialization strategy? When do you expect kind of this PNS portfolio to become a more significant contributor to revenue?

Speaker 2

Hi, Caitlin. Thanks for the question. Yeah, we're really excited about this business. A reminder that it's a very fast-growing market and a new platform that you referred to there, it's going to help patients who are coping with this unbearable chronic peripheral pain. I think it's important to keep in mind. Why? Because we have a patented electric field conduction technology with the integrated pulse generator that potentially reaches those deeper, larger nerves, which could be easier for the doctor and beneficial for the patient. To your question, in the back half of this year, we'll do a limited launch, and then we'll rapidly ramp in 2026. While we're not giving guidance on next year, I'll broaden it a little bit.

Our initial thoughts are that this business, combined with our new PRP platform, that those two alone have the potential to generate 200 basis points of growth next year for the company overall and ramp from there. That gives you a feel for when we believe this will start being a more meaningful contributor to our growth profile. Of course, we'll update you and set expectations as we learn more in the early stages of both of those launches.

That's great, thanks. Are there updates to the tariff expectations? What sort of increase, any updates to any potential impact to HA?

Speaker 7

Yeah, thanks, Caitlin. I think when we talked about this in the first quarter, it was roughly, like, you know, $1 million of tariff impacts. You know, today, as we said in the prepared remarks, we see about $3 million of an impact. That's, you know, with all of the news that we know through yesterday. Obviously, this is a very volatile situation and changes day to day. Overall, between tariffs and FX, we've absorbed $5 million of those headwinds and maintained our guidance. We'll continue to monitor this and be responsible with engaging and managing the P&L accordingly. Again, $3 million is what we expect, and that's really going to be coming in the back half of the year. We've had a little bit in the first half, but most of the tariff headwind will be in the back half of the year.

The FX headwind is already behind us here today to about $2 million that we've all contained within the guidance that we've provided.

Speaker 2

Yeah, and Caitlin, I'll just add that I think it speaks to the power of our P&L, of the strength and agility that we have. You know, as Mark mentioned, FX and tariffs combined have created that $5 million headwind, but we believe we can manage through that and deliver on our goals, which, you know, again, speaks to the power of our P&L.

Great, thanks for taking the questions.

Thank you, Caitlin.

Speaker 6

That concludes our Q&A session. I'll now turn the conference back over to Rob Claypoole for closing remarks.

Speaker 2

All right, thanks everyone for your interest in Bioventus. Once again, we delivered a solid performance throughout our business in the second quarter, and we are confident in our ability to build on our momentum to deliver above-market revenue growth, improve profitability, and accelerate our cash flow to create significant shareholder value. Thanks for joining the call.

Speaker 6

This concludes today's conference call. You may now disconnect.